The new medicine can be the first to stop deadly fatty liver disease

The study, published in the edition of August 23, 2025 on the Internet LancetIt was found that the drug, Ion224, targets the liver enzyme called DGAT2, which plays a major role in how the liver produces and stores fat. By preventing this enzyme, the drug helps reduce the accumulation of fat and inflammation, which are two main liver damage drivers in the mash.

“This study is a pivotal progress in the abandoned control,” said Rohit Lomba, a doctorate in medicine, the main researcher for studying the study and head of the Department of Diseases and Liver Science at the University of California, San Diego at the University of California Medical College at San Diego. “By preventing DGAT2, boycotting the disease process in the radical cause, stopping the accumulation of fats and infections in the liver.”

The multi -centers clinical experiment included IIB 160 of adults who suffer from mash and early fibrosis to the moderate across the United States. Participants received monthly injections from the medicine in various doses or fake for one year. At the top of the dose, 60 % showed noticeable improved liver health compared to the places of a placebo. These benefits occurred regardless of weight change, indicating that the drug can be used alongside other treatments. The drug showed any serious side effects associated with treatment.

Hormones, officially known as NASH, affects people with metabolic conditions such as obesity and type 2 diabetes. It is often called a “silent” disease because it can progress for years without symptoms.

More than 100 million people may be affected by the forms of fatty liver disease in the United States, and up to 1 in 4 adults may be affected all over the world, according to centers of control and prevention control. If left without treatment, mash can advance to liver failure and often require transplant.

“This is the first medicine of its kind to show a real biological effect on the mash,” Lomba said. “If these results are confirmed in the experiments of the third stage, we may finally be able to provide targeted treatment that stops and reflects the damage of the liver before it advances to life -threatening stages.”

Lomba, the director of the MALD LED Research Center at the University of California, San Diego, a digestive pathologist and liver specialist at the University of California at San Diego Health, adds that for patients and families affected by this serious condition, these results bring new hope for better care and outputs. And it confirms that early intervention and targeted treatments may also help reduce the burden on health care systems by preventing costly and complex liver disease.

The following steps include a larger clinical trial to approach this treatment is widely available.

Among the authors participating in the study, Erine Morgan, Kevan Yyisevi, Dan Lee, Richard Jerry, Sanjay Bhaanot, are all Ayonis medicines, Naeem El Khoury, Arizona Keep Hildh.

The financing for this research came from Ionis Pharmaceuticals (Ion224-CS2).